14th Stakeholders’ Meeting
Critical challenges to malaria elimination in S.E. Asia

Bali | 11 – 12 October 2017

Ms. Lily Su, Senior Vice President, Guilin Pharmaceutical

Defeating Malaria Together
Artesun®:
Increasing patient survival through WHO’s recommended treatment for severe malaria

Lily Su
Guilin Pharmaceutical Co., Ltd.
Bali, 12.10.2017
History of Injectable Artesuante
From Artemisinin to Injectable Artesunate

DISCOVERY OF ARTEMISININ
TU Youyou
2015 Nobel Prize Winner
China Academy of Chinese Medical Sciences

INNOVATION OF ARTESUNATE
LIU Xu
Chief Technology Officer
Guilin Pharmaceutical Co., Ltd.
The Story of China’s No.1 New Drug

- **1972**: Discovery of Artemisinin
- **1977**: Innovation of Artesunate as API (Guilin)
- **1978**: Innovation of Injectable artesunate (Guilin)
- **1980-1986**: Pre-clinical and clinical research on artemisinin derivatives
- **1987**: Authorization of Chinese New Drug License to IV Artesunate
- **1990+**: Clinical studies on IV AS outside China
- **1994**: Thai FDA approved IV AS, 1st MA abroad
- **2006**: SEAQUAMAT Study
  - WHO recommendation as 1st line treatment of severe malaria in adults
- **2011**: WHO recommendation as 1st line treatment of severe malaria in children
- **2010**: WHO PQ of Artesun® AQUAMAT Study
- **2015**: List of the French Medical Journal Prescrire

**THE LANCET AQUAMAT**

*MMV*
Make Injectable Artesunate available

- To make a quality guaranteed life-saving product, we

  5 years GMP upgrading (2005-2010) + A customer friendly package + For all age groups (30mg/60mg/120mg)
The deployment of Inj AS in Africa
Malaria Market: Public Sector

**International level**
- Guideline Definition
  - World Health Organization
- Regulatory Affairs
  - Quality assured antimalarials
  - WHO PQ / ERP
- Main Donors
  - UNITAID
  - UNICEF
  - The Global Fund
  - USAID
  - CHINA AID

**Country level**
- National Guidelines
  - National Malaria Control Programs
- Regulatory Affairs
  - Local Registration
- Main Funding
  - Governments
  - NGOs
  - Foundations

**Prevention**
- Uncomplicated malaria
- Severe malaria

Make a drug available is just the first step
Malaria market: Private sector

Make a drug available is just the first step
Artesun® is marketed in 30 African countries

From 2011 to 2016
We supplied
70000000+ vials
Treated
10000000+ patients
Saved additional
260000+ lives

1. Inj AS 60mg./ vial
2. 6.5 vials / patient
3. Estimation based on the results of AQUAMAT study
Move forward, from PQ to the field…

A handbook on deployment of inj AS in Africa
In cooperation with African experts

DHART study on Inj AS post-treatment haemolysis
In cooperation with MORU

An operational research on scaling up Inj AS in Africa (MATIAS)
In cooperation with MMV

Make a drug available is just the first step
A partner to the Fight against Malaria

- The malaria prevention cartoon project
- Malaria camp
- World Malaria Day

Community
Raise public awareness

Healthcare professionals
Link the front edge and the front line

- The eCME project
- Train the trainers / CMEs on Inj AS
- Development of job aid tools of Inj AS for the field
- A global Pharmacovigilance system

Make a drug available is just the first step
From bench to bedside, together we built a landmark of Chinese antimalarials
END MALARIA FOR GOOD

Thank you!

FOSUN PHARMA